Through our patented, liquid biopsy process, Circulogene delivers tumor monitoring with minimal-volumes of blood.
Circulogene only requires a minimal-volume of blood.
Circulogene’s tests locate and capture cell-free DNA, identifying and quantifying any known tumor mutations for accurate reporting and monitoring.
In our personalized gene reports, we provide further information on current FDA-approved treatment options for the tumor DNA identified.
The efficiency of Circulogene’s process empowers you and your doctor to closely monitor tumor responsiveness and adjust treatment protocols. Turnaround time is five to seven days, which is much faster than tissue biopsy results.